News for Lantern Pharma Inc. (LTRN)

AUSTIN, Texas, July 16, 2025 (GLOBE NEWSWIRE) -- via IBN -- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform to transform the cost, pace and precision of oncology drug development, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts.

Lantern Pharma (LTRN) has introduced a groundbreaking AI-driven module within its RADR platform, aiming to enhance the prediction of the effectiveness of combin

Lantern Pharma Inc. (LTRN) launches an AI-powered module to enhance prediction of cancer treatment efficacy, focusing on DNA-damaging agents and DNA repair

Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, toda

Lantern Pharma Inc.

Lantern Pharma (LTRN) has unveiled promising preclinical data for its innovative drug candidate, LP-184, aimed at treating atypical teratoid rhabdoid tumors (AT

Operator: Good morning, and welcome to our First Quarter 2025 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.

The following slide deck was published by Lantern Pharma Inc.

Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ETCompany ParticipantsPanna Sharma - President & CEODavid...

Lantern Pharma (LTRN) achieved substantial progress in its AI-driven drug development pipeline during Q1 2025. Completion of LP-184 Phase 1a clinical tr

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learn

Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platfor

Lantern Pharma, trading under the ticker LTRN, has received approval from the U.S. Food and Drug Administration to amend its Investigational New Drug (IND) appl

Lantern Pharma, with the ticker LTRN, has successfully secured FDA approval for their investigational new drug application. This clearance allows them to procee

\n Lantern Pharma Inc. (LTRN) receives FDA clearance for an Investigational New Drug (IND) application for LP-184 in Triple Negative Breast Cancer (TNBC).

\nLantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platfor

Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones for...

Cash Position: Approximately $24 million in cash, cash equivalents, and marketable securities as of December 31, 2024.Clinical Trials: Significant progress in